GB2214185B - Amphiregulin glycoprotein exhibiting bifunctional cell growth regulatory activity - Google Patents

Amphiregulin glycoprotein exhibiting bifunctional cell growth regulatory activity

Info

Publication number
GB2214185B
GB2214185B GB8901469A GB8901469A GB2214185B GB 2214185 B GB2214185 B GB 2214185B GB 8901469 A GB8901469 A GB 8901469A GB 8901469 A GB8901469 A GB 8901469A GB 2214185 B GB2214185 B GB 2214185B
Authority
GB
United Kingdom
Prior art keywords
amphiregulin
cell growth
regulatory activity
growth regulatory
glycoprotein exhibiting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
GB8901469A
Other languages
English (en)
Other versions
GB2214185A (en
GB8901469D0 (en
Inventor
Mohammed Shoyab
Vicki L Mcdonald
James G Bradley
Greg Plowman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncogen LP
Original Assignee
Oncogen LP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/297,816 external-priority patent/US5115096A/en
Application filed by Oncogen LP filed Critical Oncogen LP
Publication of GB8901469D0 publication Critical patent/GB8901469D0/en
Publication of GB2214185A publication Critical patent/GB2214185A/en
Application granted granted Critical
Publication of GB2214185B publication Critical patent/GB2214185B/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/108—Plasmid DNA episomal vectors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
GB8901469A 1988-01-25 1989-01-24 Amphiregulin glycoprotein exhibiting bifunctional cell growth regulatory activity Expired - Fee Related GB2214185B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14832788A 1988-01-25 1988-01-25
US18188488A 1988-04-15 1988-04-15
US07/297,816 US5115096A (en) 1988-04-15 1989-01-17 Amphiregulin: a bifunctional growth modulating glycoprotein

Publications (3)

Publication Number Publication Date
GB8901469D0 GB8901469D0 (en) 1989-03-15
GB2214185A GB2214185A (en) 1989-08-31
GB2214185B true GB2214185B (en) 1992-06-17

Family

ID=27386678

Family Applications (1)

Application Number Title Priority Date Filing Date
GB8901469A Expired - Fee Related GB2214185B (en) 1988-01-25 1989-01-24 Amphiregulin glycoprotein exhibiting bifunctional cell growth regulatory activity

Country Status (24)

Country Link
US (1) US5830995A (enExample)
JP (1) JPH02104596A (enExample)
CN (1) CN1038126A (enExample)
AT (1) AT399720B (enExample)
AU (1) AU623109B2 (enExample)
BE (1) BE1004201A5 (enExample)
CH (1) CH681080A5 (enExample)
DE (1) DE3902157A1 (enExample)
DK (1) DK29989A (enExample)
ES (1) ES2016432A6 (enExample)
FI (1) FI890312A7 (enExample)
FR (1) FR2628109B1 (enExample)
GB (1) GB2214185B (enExample)
GR (1) GR1000849B (enExample)
HU (1) HUT52545A (enExample)
IE (1) IE61146B1 (enExample)
IL (1) IL89033A (enExample)
IT (1) IT1229504B (enExample)
MY (1) MY104980A (enExample)
NL (1) NL8900178A (enExample)
NO (1) NO177788C (enExample)
NZ (1) NZ227729A (enExample)
SE (1) SE504554C2 (enExample)
YU (1) YU16989A (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5262298A (en) * 1989-05-12 1993-11-16 The State Of Oregon Acting By And Through The State Board Of Education On Behalf Of The Oregon Health Sciences University Method to assess the ability of a substance to inhibit or stimulate keratinocyte autocrine factor production
EP0444961A1 (en) * 1990-03-02 1991-09-04 Bristol-Myers Squibb Company Her3: A novel EGF receptor homolog
JPH06502538A (ja) * 1990-10-16 1994-03-24 ザ　チルドレンズメディカルセンターコーポレーション 上皮細胞成長因子（ｅｇｆ）との相同性をもつヘパリン結合性マイトジェン
US5302706A (en) * 1991-12-16 1994-04-12 Baylor College Of Medicine Senescent cell derived inhibitors of DNA synthesis
US6235884B1 (en) 1993-06-15 2001-05-22 Scios Nova, Inc. Heparin binding mitogen with homology to epidermal growth factor (EGF)
US5633147A (en) * 1994-03-08 1997-05-27 Human Genome Sciences, Inc. Transforming growth factor αH1
WO1997023507A2 (en) * 1995-12-22 1997-07-03 Innogenetics N.V. New form of amphiregulin, methods for producing and using the same and compositions comprising the same
US6852506B1 (en) 1996-04-10 2005-02-08 Human Genome Sciences, Inc. Extracellular/epidermal growth factor-like protein
US5948889A (en) * 1996-05-21 1999-09-07 Case Western Reserve University Compositions and methods for screening antimicrobials
WO1998046746A1 (en) * 1997-04-11 1998-10-22 Human Genome Sciences, Inc. Extracellular/epidermal growth factor like protein
US20060276629A9 (en) * 1999-12-17 2006-12-07 Hildebrand William H Purification and characterization of soluble human HLA proteins
US7541429B2 (en) * 2000-10-10 2009-06-02 The Board Of Regents Of The University Of Oklahoma Comparative ligand mapping from MHC positive cells
US20050003483A1 (en) * 2000-10-10 2005-01-06 Hildebrand William H. Comparative ligand mapping from MHC class 1 positive cells
US20070099182A1 (en) * 2000-10-10 2007-05-03 Hildebrand William H Comparative ligand mapping from MHC class I positive cells
US20090062512A1 (en) * 2000-10-10 2009-03-05 Hildebrand William H Comparative ligand mapping from MHC class I positive cells
US20070026433A1 (en) 2001-03-09 2007-02-01 Hildebrand William H Epitope testing using soluble HLA
US20020122820A1 (en) * 2001-01-16 2002-09-05 Hildebrand William H. Soluble MHC artificial antigen presenting cells
WO2002059376A1 (en) * 2001-01-23 2002-08-01 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of human colon cancer
CA2440399C (en) * 2001-03-09 2008-11-18 Rico Buchli Epitope testing using hla
US20040126829A1 (en) * 2001-12-18 2004-07-01 Hildebrand William H. Anti-HLA assay and methods
RU2224255C2 (ru) * 2002-04-15 2004-02-20 Государственное учреждение Нижегородский научно-исследовательский кожно-венерологический институт Способ прогнозирования течения псориаза
CA2496732A1 (en) * 2002-08-20 2004-03-04 Biosurface Engineering Technologies, Inc. Synthetic heparin-binding growth factor analogs
US8227411B2 (en) 2002-08-20 2012-07-24 BioSurface Engineering Technologies, Incle FGF growth factor analogs
US7598224B2 (en) * 2002-08-20 2009-10-06 Biosurface Engineering Technologies, Inc. Dual chain synthetic heparin-binding growth factor analogs
US7223393B2 (en) 2003-02-07 2007-05-29 Pdl Biopharma, Inc Amphiregulin antibodies and their use to treat cancer and psoriasis
EP1449538A1 (en) * 2003-02-21 2004-08-25 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibition of TACE or amphiregulin for the modulation of EGF receptor signal transactivation
US20050130897A1 (en) * 2003-12-11 2005-06-16 Ma Jian-Xing Compounds useful in inhibiting vascular leakage, inflammation and fibrosis and methods of making and using same
US20080227696A1 (en) * 2005-02-22 2008-09-18 Biosurface Engineering Technologies, Inc. Single branch heparin-binding growth factor analogs
JP4895826B2 (ja) 2004-02-20 2012-03-14 バイオサーフェス エンジニアリング テクノロジーズ，インク． 骨形成蛋白−２の正のモジュレーター
CA2568427A1 (en) * 2004-05-27 2006-01-12 Tanox, Inc. Method for preventing and treating mast cell mediated diseases
US7820172B1 (en) 2006-06-01 2010-10-26 Biosurface Engineering Technologies, Inc. Laminin-derived multi-domain peptides
CA2692240C (en) 2006-06-22 2018-03-13 Biosurface Engineering Technologies, Inc. Composition and method for delivery of bmp-2 amplifier/co-activator for enhancement of osteogenesis
GB0807018D0 (en) * 2008-04-17 2008-05-21 Fusion Antibodies Ltd Antibodies and treatment
WO2010137012A1 (en) 2009-05-25 2010-12-02 Ramot At Tel-Aviv University Ltd. Peptide therapy for amphiregulin mediated diseases
DE102011056933A1 (de) * 2011-12-22 2013-06-27 Bayerische Motoren Werke Aktiengesellschaft Interieurbauteil für ein Kraftfahrzeug
AU2015204540B2 (en) 2014-01-12 2020-03-19 Igf Oncology, Llc Fusion proteins containing insulin-like growth factor-1 and epidermal growth factor and variants thereof and uses thereof
WO2015148960A1 (en) 2014-03-28 2015-10-01 The Board Of Regents Of The University Of Oklahoma Compositions comprising soluble hla/m. tuberculosis-specific ligand complexes and methods of production and use thereof
US20190016754A1 (en) * 2015-11-10 2019-01-17 Proteothera, Inc. Methods of producing and purifying matrix-binding fusion proteins by ion-exchange chromatography
CA3059593A1 (en) 2017-05-21 2018-11-29 Igf Oncology, Llc An insulin-like growth factor-chemotherapeputic conjugate for treating myelodysplastic syndrome
CN110531023B (zh) * 2019-10-08 2024-06-14 安徽理工大学 一种薄层色谱分析仪
CN112779209B (zh) * 2019-11-08 2023-01-24 合肥中科普瑞昇生物医药科技有限公司 原代乳腺上皮细胞培养基、培养方法及其应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5115096A (en) * 1988-04-15 1992-05-19 Oncogen Amphiregulin: a bifunctional growth modulating glycoprotein

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Pro. Natl. Acad. Sci. USA, 1988, 85(17), 6528-6532. *

Also Published As

Publication number Publication date
DK29989D0 (da) 1989-01-24
SE8900247L (sv) 1989-07-26
NZ227729A (en) 1992-02-25
DK29989A (da) 1989-07-26
YU16989A (en) 1991-10-31
IT1229504B (it) 1991-09-03
HUT52545A (en) 1990-07-28
BE1004201A5 (fr) 1992-10-13
FI890312A0 (fi) 1989-01-20
NO890299L (no) 1989-07-26
MY104980A (en) 1994-07-30
IT8919186A0 (it) 1989-01-25
IL89033A0 (en) 1989-08-15
AT399720B (de) 1995-07-25
GB2214185A (en) 1989-08-31
AU2876989A (en) 1989-08-24
GB8901469D0 (en) 1989-03-15
DE3902157A1 (de) 1989-07-27
ATA14789A (de) 1994-11-15
IE61146B1 (en) 1994-10-05
SE8900247D0 (sv) 1989-01-24
FR2628109B1 (fr) 1993-04-09
NO890299D0 (no) 1989-01-24
CN1038126A (zh) 1989-12-20
NO177788B (no) 1995-08-14
FI890312L (fi) 1989-07-26
FR2628109A1 (fr) 1989-09-08
NL8900178A (nl) 1989-08-16
CH681080A5 (enExample) 1993-01-15
FI890312A7 (fi) 1989-07-26
AU623109B2 (en) 1992-05-07
NO177788C (no) 1995-11-22
IE890207L (en) 1989-07-25
SE504554C2 (sv) 1997-03-03
GR1000849B (el) 1993-02-17
US5830995A (en) 1998-11-03
GR890100037A (en) 1990-01-31
IL89033A (en) 1994-05-30
JPH02104596A (ja) 1990-04-17
ES2016432A6 (es) 1990-11-01

Similar Documents

Publication Publication Date Title
IL89033A0 (en) Bifunctional growth modulating glycoprotein named amphiregulin and its production
GB8811618D0 (en) Plant container
IL92458A0 (en) Plant harvester
GB8916692D0 (en) Secateurs
GB2222063B (en) Plant container assembly
EP0466780A4 (en) Megakaryocyte growth promoting activity
GB2237965B (en) Plant pot
EP0489721A3 (en) Endothelial cell harvester
GB8629997D0 (en) Cell growth regulatory factor
GB8606080D0 (en) Plant container
GB8604186D0 (en) Plant container
GB2227164B (en) Plant pot support
GB8813556D0 (en) Plant carrier
GB2231563B (en) Plant antitranspirant
GB2196521B (en) Plant container
GB2199475B (en) Plant cultivation container
ZA89549B (en) Amphiregulin:a novel bifunctional growth modulating glycoprotein
IE893992L (en) Potentiating natural killer cell activity
GB8810442D0 (en) Easy gardener
GB8803358D0 (en) Container for plants
GB8828729D0 (en) Neutrophil-stimulating activity i
GB8828728D0 (en) Neutrophil-stimulating activity i
GB8828727D0 (en) Neutrophil-stimulating activity i
GB8801415D0 (en) Sectional plant container
GB8809678D0 (en) Plant support

Legal Events

Date Code Title Description
PCNP Patent ceased through non-payment of renewal fee

Effective date: 19990124